Jefferies analyst Kambiz Yazdi initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $23 price target Avalo is a clinical stage biotechnology company focused on immunology and inflammation led by a veteran management team, the analyst tells investors in a research note. The firm says Avalo’s lead asset AVTX-009 is an IL-1beta antibody in Phase 2 for the treatment of moderate to severe hidradenitis suppurativa with topline data expected in 2026. It thinks AVTX-009 is de-risked in part by lutikizumab data and that Avalo has an angle to show a differentiated profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Promising Outlook for Avalo Therapeutics’ AVTX-009 in HS Treatment
- Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS Treatment
- Avalo Therapeutics reports FY24 EPS ($20.91) vs ($113.58) last year
- Walgreens downgraded, Cava Group upgraded: Wall Street’s top analyst calls
- Piper Sandler bullish on Avalo Therapeutics, initiates with an Overweight